Lantheus Holdings Inc
NASDAQ:LNTH
Lantheus Holdings Inc
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes.
This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes.
This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
2025 Revenue: Lantheus reported Q4 revenue of $406.8 million, up 4%, and full year revenue of $1.5416 billion, up 0.5%.
PYLARIFY Dynamics: PYLARIFY Q4 revenue was $240.2 million, flat sequentially but down 9.7% year-over-year; 2026 guidance anticipates PYLARIFY revenue declining 8–10% due to modest price erosion and competitive dynamics.
Neuraceq Growth: Neuraceq delivered $31 million in Q4 and is expected to grow at a triple-digit rate (140–150%) in 2026, supported by expanding manufacturing and rising Alzheimer's imaging demand.
2026 Outlook: Company guides 2026 revenue to $1.4–1.45 billion and EPS of $5.00–$5.25, with new product launches expected to materially impact results in 2027 rather than 2026.
Strategic Focus: Lantheus is doubling down on radiodiagnostics, optimizing cost structure, and pursuing alternatives for its radiotherapeutic assets, while pausing major M&A.
Pipeline Milestones: Up to four potential FDA approvals in 2026, including new PSMA PET formulation and OCTEVY, but no meaningful revenue from these launches expected until 2027.
Cash & Capital: Free cash flow in Q4 was $81.4 million; company repurchased $100 million of shares and ended with $359.1 million in cash.
